Page last updated: 2024-08-25

clarithromycin and isoxazoles

clarithromycin has been researched along with isoxazoles in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kanoh, S; Kubo, K; Rubin, BK; Tanabe, T; Tsushima, K; Yamazaki, Y	1
Andries, K; Bantubani, N; De Marez, T; Diacon, AH; Donald, PR; Grobusch, M; Lounis, N; Mahanyele, R; McNeeley, DF; Meyvisch, P; Narasimooloo, R; Patientia, RF; Pym, A; van Heeswijk, R	1
Butler-Laporte, G; Menzies, D; Winters, N	1

Reviews

1 review(s) available for clarithromycin and isoxazoles

Article	Year
Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. The European respiratory journal, 2015, Volume: 46, Issue:5 Topics: Amoxicillin; Antitubercular Agents; Azithromycin; Cilastatin; Clarithromycin; Clavulanic Acid; HIV Infections; Humans; Imipenem; Isoxazoles; Macrolides; Meropenem; Mycobacterium tuberculosis; Oxazolidinones; Randomized Controlled Trials as Topic; Thienamycins; Thioridazine; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization	2015

Article

Year

Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.

The European respiratory journal, 2015, Volume: 46, Issue:5

Topics: Amoxicillin; Antitubercular Agents; Azithromycin; Cilastatin; Clarithromycin; Clavulanic Acid; HIV Infections; Humans; Imipenem; Isoxazoles; Macrolides; Meropenem; Mycobacterium tuberculosis; Oxazolidinones; Randomized Controlled Trials as Topic; Thienamycins; Thioridazine; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization

2015

Trials

1 trial(s) available for clarithromycin and isoxazoles

Article	Year
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Dapsone; Diarylquinolines; Erythromycin; Female; Humans; Isoxazoles; Male; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis, Multidrug-Resistant	2012

Article

Year

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Dapsone; Diarylquinolines; Erythromycin; Female; Humans; Isoxazoles; Male; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis, Multidrug-Resistant

2012

Other Studies

1 other study(ies) available for clarithromycin and isoxazoles

Article	Year
Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells. American journal of respiratory cell and molecular biology, 2011, Volume: 45, Issue:5 Topics: Bronchi; Cell Differentiation; Clarithromycin; Enzyme Inhibitors; ErbB Receptors; Flavonoids; Goblet Cells; Heterocyclic Compounds, 3-Ring; Humans; Hyperplasia; Interleukin-13; Isoxazoles; Janus Kinases; Leflunomide; MAP Kinase Signaling System; Mucin 5AC; Mucus; NF-kappa B; Protein Synthesis Inhibitors; Pyridines; Respiratory Mucosa; Signal Transduction; STAT6 Transcription Factor	2011

Article

Year

Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells.

American journal of respiratory cell and molecular biology, 2011, Volume: 45, Issue:5

Topics: Bronchi; Cell Differentiation; Clarithromycin; Enzyme Inhibitors; ErbB Receptors; Flavonoids; Goblet Cells; Heterocyclic Compounds, 3-Ring; Humans; Hyperplasia; Interleukin-13; Isoxazoles; Janus Kinases; Leflunomide; MAP Kinase Signaling System; Mucin 5AC; Mucus; NF-kappa B; Protein Synthesis Inhibitors; Pyridines; Respiratory Mucosa; Signal Transduction; STAT6 Transcription Factor

2011